Clinical Trial Update: Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether pausing versus continuing treatment is preferred in metastatic renal cell carcinoma patients who have good or intermediate ri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score | Phase 3 | Status: ACTIVE_NOT_RECRUITING